Humana Inc. (HUM) Lowered to “Hold” at ValuEngine

ValuEngine downgraded shares of Humana Inc. (NYSE:HUM) from a buy rating to a hold rating in a research report released on Tuesday.

Other research analysts have also issued reports about the stock. UBS AG restated a neutral rating and set a $237.00 target price (up from $205.00) on shares of Humana in a research report on Wednesday, June 28th. BidaskClub lowered shares of Humana from a buy rating to a hold rating in a research report on Tuesday, June 13th. Zacks Investment Research lowered shares of Humana from a hold rating to a sell rating in a research report on Thursday, July 27th. Piper Jaffray Companies restated a buy rating and set a $246.00 target price on shares of Humana in a research report on Friday, July 14th. Finally, Oppenheimer Holdings, Inc. upped their target price on shares of Humana from $236.00 to $255.00 and gave the stock an outperform rating in a research report on Thursday, August 3rd. Eleven analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $251.60.

Shares of Humana (NYSE HUM) opened at 240.49 on Tuesday. The company has a 50-day moving average price of $248.64 and a 200 day moving average price of $235.08. The firm has a market capitalization of $34.75 billion, a PE ratio of 19.78 and a beta of 0.86. Humana has a 12-month low of $163.50 and a 12-month high of $259.76.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share for the quarter, topping the consensus estimate of $3.08 by $0.41. Humana had a net margin of 3.37% and a return on equity of 15.85%. The company had revenue of $13.53 billion for the quarter, compared to analyst estimates of $13.61 billion. During the same period in the prior year, the business posted $2.30 earnings per share. On average, equities analysts expect that Humana will post $11.56 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://ledgergazette.com/2017/10/11/humana-inc-hum-lowered-to-hold-at-valuengine.html.

The company also recently announced a dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 29th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, September 28th. Humana’s dividend payout ratio (DPR) is currently 13.06%.

In related news, VP Timothy S. Huval sold 7,803 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $258.14, for a total transaction of $2,014,266.42. Following the sale, the vice president now owns 8,831 shares in the company, valued at $2,279,634.34. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Bruce D. Broussard sold 12,000 shares of the firm’s stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $251.88, for a total transaction of $3,022,560.00. Following the sale, the chief executive officer now owns 80,086 shares in the company, valued at approximately $20,172,061.68. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 55,595 shares of company stock worth $14,133,706. 0.80% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Prisma Capital Partners LP acquired a new stake in Humana during the second quarter worth approximately $7,122,000. Teachers Advisors LLC boosted its position in Humana by 31.6% during the second quarter. Teachers Advisors LLC now owns 630,835 shares of the insurance provider’s stock worth $151,792,000 after acquiring an additional 151,603 shares during the last quarter. Federated Investors Inc. PA boosted its position in Humana by 608.1% during the second quarter. Federated Investors Inc. PA now owns 34,626 shares of the insurance provider’s stock worth $8,331,000 after acquiring an additional 29,736 shares during the last quarter. Commonwealth Bank of Australia boosted its position in Humana by 4.0% during the second quarter. Commonwealth Bank of Australia now owns 20,316 shares of the insurance provider’s stock worth $4,887,000 after acquiring an additional 775 shares during the last quarter. Finally, Cipher Capital LP boosted its position in Humana by 7.7% during the second quarter. Cipher Capital LP now owns 9,734 shares of the insurance prov

Other research analysts have also issued reports about the stock. UBS AG restated a neutral rating and set a $237.00 target price (up from $205.00) on shares of Humana in a research report on Wednesday, June 28th. BidaskClub lowered shares of Humana from a buy rating to a hold rating in a research report on Tuesday, June 13th. Zacks Investment Research lowered shares of Humana from a hold rating to a sell rating in a research report on Thursday, July 27th. Piper Jaffray Companies restated a buy rating and set a $246.00 target price on shares of Humana in a research report on Friday, July 14th. Finally, Oppenheimer Holdings, Inc. upped their target price on shares of Humana from $236.00 to $255.00 and gave the stock an outperform rating in a research report on Thursday, August 3rd. Eleven analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $251.60.

Shares of Humana (NYSE HUM) opened at 240.49 on Tuesday. The company has a 50-day moving average price of $248.64 and a 200 day moving average price of $235.08. The firm has a market capitalization of $34.75 billion, a PE ratio of 19.78 and a beta of 0.86. Humana has a 12-month low of $163.50 and a 12-month high of $259.76.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share for the quarter, topping the consensus estimate of $3.08 by $0.41. Humana had a net margin of 3.37% and a return on equity of 15.85%. The company had revenue of $13.53 billion for the quarter, compared to analyst estimates of $13.61 billion. During the same period in the prior year, the business posted $2.30 earnings per share. On average, equities analysts expect that Humana will post $11.56 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://ledgergazette.com/2017/10/11/humana-inc-hum-lowered-to-hold-at-valuengine.html.

The company also recently announced a dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 29th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, September 28th. Humana’s dividend payout ratio (DPR) is currently 13.06%.

In related news, VP Timothy S. Huval sold 7,803 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $258.14, for a total transaction of $2,014,266.42. Following the sale, the vice president now owns 8,831 shares in the company, valued at $2,279,634.34. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Bruce D. Broussard sold 12,000 shares of the firm’s stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $251.88, for a total transaction of $3,022,560.00. Following the sale, the chief executive officer now owns 80,086 shares in the company, valued at approximately $20,172,061.68. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 55,595 shares of company stock worth $14,133,706. 0.80% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Prisma Capital Partners LP acquired a new stake in Humana during the second quarter worth approximately $7,122,000. Teachers Advisors LLC boosted its position in Humana by 31.6% during the second quarter. Teachers Advisors LLC now owns 630,835 shares of the insurance provider’s stock worth $151,792,000 after acquiring an additional 151,603 shares during the last quarter. Federated Investors Inc. PA boosted its position in Humana by 608.1% during the second quarter. Federated Investors Inc. PA now owns 34,626 shares of the insurance provider’s stock worth $8,331,000 after acquiring an additional 29,736 shares during the last quarter. Commonwealth Bank of Australia boosted its position in Humana by 4.0% during the second quarter. Commonwealth Bank of Australia now owns 20,316 shares of the insurance provider’s stock worth $4,887,000 after acquiring an additional 775 shares during the last quarter. Finally, Cipher Capital LP boosted its position in Humana by 7.7% during the second quarter. Cipher Capital LP now owns 9,734 shares of the insurance provider’s stock worth $2,342,000 after acquiring an additional 698 shares during the last quarter. Hedge funds and other institutional investors own 95.12% of the company’s stock.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Humana Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply